Marché mondial de la carence en arginase – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché du déficit en arginase

Le déficit en arginase est un type rare de déficit, dont on estime qu'il touche environ 1 personne sur 300 000 à 1 000 000. Cependant, ces troubles sont souvent sous-diagnostiqués car les troubles du cycle de l'urée tels que le déficit en NAGS passent souvent inaperçus, ce qui rend difficile de déterminer la fréquence réelle des troubles du cycle de l'urée dans la population générale. Les progrès technologiques dans le traitement et le diagnostic et l'augmentation des troubles génétiques héréditaires stimulent également la croissance du marché. Mais les effets graves liés au traitement, le manque d'étiologie et le faible taux d'incidence peuvent entraver le marché du déficit en arginase.

Data Bridge Market Research analyse le taux de croissance du marché de la carence en arginase au cours de la période de prévision 2023-2030. Le TCAC attendu du marché de la carence en arginase a tendance à être d'environ 4 % au cours de la période de prévision mentionnée. Le marché était évalué à 100 millions USD en 2022 et devrait atteindre 136,8 millions USD d'ici 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de recherche sur le marché de Data Bridge comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée et segmentation du marché du déficit en arginase

Market Definition

Arginase deficiency is a type of inherited metabolic disorder that is characterized by the partial and complete lack of arginase enzyme in the red blood cells and liver. The lack of arginase enzyme causes excessive accumulation of nitrogen in the form of arginine and ammonia  in the cerebrospinal fluid and blood. If the deficiency is not treated on time properly, it may lead to spasticity, short stature, seizures, and intellectual disability may occurs. The accumulation of ammonia in the blood causes the symptoms of NAGS deficiency. In the most extreme cases, the symptoms of this deficiency occur within 24-72 hours after birth.

Arginase Deficiency Market Dynamics

Drivers

• Growing Adoption of Injectable Route of Administration

Injection arginase deficiency drugs are used in cases where oral medications are either unavailable or unsuitable for specific patients such as infants, children, and those suffering from severe kidney disease, and other conditions that prevent normal pill consumption. In addition to this, it also aids in improving patient adherence to their prescribed medication, further improving their health condition.

Opportunities

• Increasing Demand For Hospitals

Drug stores and hospitals consider to be the major application segments of arginase deficiency drugs. In 2015, the hospital segment dominated the global market with a more than 80% revenue share. The segment is estimated to witness major growth due to increasing healthcare expenditure and a growing number of patients suffering from life-threatening diseases such as cancer, who require intravenous (IV) nutrition for treatment.

• Varied Options For Diagnostic Tests

A diagnosis of NAGS deficiency can be done through a detailed patient or family history, identification of specialized findings, and a variety of particular tests. Blood tests may show excessive amounts of ammonia in the blood, which is the primary finding of urea cycles disorders. Though, increased levels of ammonia in the blood may describe other disorders such as the congenital lactic acidosis, organic acidemias, and fatty acid oxidation disorders. Urea cycles disorders can be distinguished from these disorders through the examination of urine for increased levels of or abnormal organic acids.

Restraints/Challenges

• Lack of Awareness

For many decades, this deficiency disease is not much known in several parts of the world. The appropriate treatment for the disease and its associated applications are unaware to the people. Thus, it hampers the market growth.   

• High Cost of Treatment Process

The enormous expenditure required for its treatment processes obstructs the market growth. Numerous market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.

This arginase deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the arginase deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Arginase Deficiency Market Scope

The arginase deficiency market is segmented on the basis of diagnosis, treatment, drug type, end-user distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Genetic Testing
• New-born Screening
• Others

Treatment

• Nitrogen-Binding Adjunctive
• Nitrogen Scavenger Drugs
• Benzoate
• Phenylacetate (PA)
• phenylbutyrate (PB)
• Anti-Seizure Drugs
• Carbamazepine
• Oxcarbazepine
• Trileptal
• Oxtellar XR
• Lamotrigine
• Lamictal
• Phenytoin
• Dilantin
• Intravenous (IV) Fluids
• Others

Drug Type

• Branded
• Generic

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Arginase Deficiency Market Regional Analysis/Insights

The arginase deficiency market is analyzed and market size insights and trends are provided by diagnosis, treatment, drug type, end-user distribution channel as referenced above.

The major countries covered in the arginase deficiency market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market due to the presence of high healthcare expenditure and research and development.

Asia-Pacific is considered to grow over the coming years due to increased advancement in the technology as well as growing healthcare expenditure.

La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales. 

Analyse du paysage concurrentiel et des parts de marché mondiales du déficit en arginase

Le paysage concurrentiel du marché de la carence en arginase fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de la carence en arginase

Les principaux acteurs opérant sur le marché du déficit en arginase comprennent :

• Horizon Therapeutics plc (Dublin)
• Les Compagnies de Santé Bausch Inc. (Canada)
• Sigmapharm Laboratories, LLC (États-Unis)
• Par Pharmaceutical. (États-Unis)
• Aeglea BioTherapeutics (Austin)

SKU-57075